Cataracts Clinical Trial
Official title:
Predictability of the IOL Position Using an Intra-operative OCT
Refractive outcome after cataract surgery mainly depends on the prediction of the
intraocular lens that is implanted in the eye during surgery.
Aim of this study is to measure the position of the lens capsule during surgery and to use
this measurements to improve post-operative refractive outcomes.
During the last decades the refractive outcome after cataract surgery improved
significantly.
The total prediction error in IOL power calculation (and therefore in the refractive
outcome) can be divided into 3 main parameters:
- Axial eye length (in mm)
- Corneal power (in dioptres)
- Estimation of post-operative anterior chamber depth (ACD) (in mm)
Since the introduction of optical biometry (IOLMaster, Carl Zeiss Meditec AG, Jena,
Germany), as a reliable non-contact measurement of the axial eye length the influence of the
error of axial length measurement on the refractive error decreased from over 50% (when
measured with applanation ultrasound) to 36%. The mean error of corneal power measurement is
approximately 22%.
These results show that the estimation of the post-operative intra-ocular lens (IOL)
position and therefore the estimated anterior chamber depth (ACD) is nowadays the main
source of error (35%to 42%) in IOL power calculation and therefore for the refractive
outcome of the patients after cataract surgery.
Early IOL power calculation formulas, such as the Binkhorst I formula, used a fixed ACD
value to predict the position of the IOL, but the refractive results were not appropriate,
because the post-operative position of the IOL varied significantly between patients. Later
observations showed a correlation between the axial eye length and the post-operative ACD
(longer=more myopic eyes showed a larger ACD post-operatively). These correlations were
taken into account in later developed formulas (such as the Binkhorst II formula).
Olsen et al. measured the post-operative ACD and substituted the predicted post-operative
ACD with the true, post-operative ACD in each case. The result after correcting the IOL
position was a highly accurate IOL power calculation, where no fudge factors were needed.
Nowadays the pre-operatively measured ACD is taken into account for several IOL power
calculation formulas, such as the Haigis formula, the Holladay II formula and the Olsen
formula.
However, this new generation of formulas uses the pre-operative ACD, without considering the
thickness of the crystalline lens. The ACD is measured as the distance between the anterior
surface of the cornea (anatomically correct would be the posterior surface of the cornea,
but in an optical context, as in IOL power calculations, the anterior surface is used) and
the anterior surface of the crystalline lens . Therefore the thickness of the crystalline
lens has a significant impact on the predicted post-operative position of the IOL. This
parameter was first taken into account by Olsen and later modified by Norrby.
It should be mentioned that IOL power calculations developed from theoretical calculations
based on Gaussian optics to regression formulas, such as the SRK formula 11 that uses
retrospective data of a large number of patients. Nowadays ray tracing is available that
uses a numerical solution to calculate the IOL power.
All these findings suggest that a proper measurement of the position and the size of the
crystalline lens as well as of the lens capsule after removing the crystalline lens is
necessary to improve IOL power calculation.
Recently a device was introduced that allows measurements of the crystalline lens as well as
the lens capsule itself after removing the crystalline lens of cataract patients
intra-operatively. This device uses optical coherence tomography (OCT) technology to create
high resolution B-scans (=images) of the anterior segment of the eye. The OCT was shown to
be highly reproducible for ACD measurements pre-operatively and small changes of the
IOL/crystalline lens can be detected.
The intra-operative OCT may allow measurements of the crystalline lens, of the lens capsule
and furthermore of the position of the IOL intra-operatively. Therefore it may be possible
for the first time, to directly observe the correlation of the position and size of the
crystalline lens to the IOL position intra-operatively.
Number of subjects In total, 50 eyes of 50 subjects will be included.
- Standard eyes (IOL power 18 - 23 D): 30 eyes
- Long (myopic) eyes (IOL power < 18 D) - 10 eyes
- Short (hyperopic) eyes (IOL power > 23 D) - 10 eyes
Study Visits On the day of pre-operative examination, the patient will undergo a full
ophthalmic assessment and routine biometry will be performed for axial length measurement
and Keratometry (IOLMaster, Carl Zeiss Meditec AG, Jena, Germany). Furthermore
pre-operatively the ACD and lens thickness (LT) will be measured (ACMaster, Carl Zeiss
Meditec AG, Jena, Germany).
Surgery is performed in topical anaesthesia. The standard preoperative therapy is
tropicamide 1% gtt, phenylephrine 2.5% gtt, cyclopentolate 1% gtt. An on-axis self-sealing
incision, injection of viscoelastic substance, capsulorhexis, phacoemulsification,
irrigation/aspiration of cortical material are performed as standard procedure. After
measurement, the IOL will be implanted using the dedicated injector system.
Intra-operative study-related measurements:
OCT scans will be performed at 4 different stages intra-operatively:
1. At the beginning of the surgery
2. After removing the natural crystalline lens with phakoemulsification and
irrigation/aspiration (I/A). The infusion handpiece of the I/A set (that is used
routinely) will be placed into the paracentesis and the bottle height will be adjusted
to control the pressure in the anterior chamber. It will be set to result in an
estimated pressure of approximately 20mmHg. Therefore a hydraulic table with memory
function will be used that can be set at exactly the same height for each patient and
the infusion bottle will be placed at a height of 27cm above the eye (27.2cmH2O =
20mmHg). Then an OCT scan will be performed.
3. Then ophthalmic viscosurgical device (OVD) is inserted and a capsular tension ring
(CTR) will be implanted. Therefore the OVD is irrigated and aspirated and the
measurement repeated.
4. Afterwards the IOL is implanted and the viscoelastic is removed.
Outcome variables
Main outcome variable:
- Intra-operative posterior capsule position with CTR in place Additional outcome
variable
- Posterior capsule position in phakic eyes
- Posterior capsule position intra-operatively without CTR
- Comparison of posterior capsule position of eyes with different axial eye length
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06005675 -
User Acceptability Evaluation of Pseudophakic Patients Previously Implanted With the TECNIS Odyssey IOL
|
||
Active, not recruiting |
NCT01382641 -
Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery
|
Phase 4 | |
Completed |
NCT01382823 -
Laser Cataract Surgery With the Femtosecond Laser Technology
|
Phase 4 | |
Completed |
NCT05991960 -
Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL
|
||
Active, not recruiting |
NCT05574959 -
Clinical Investigation of the TECNIS® Next-Generation Intraocular Lens, Model DEN00V
|
N/A | |
Completed |
NCT02492659 -
Clinical Research of Femtosecond Laser-Assisted Cataract Surgery
|
N/A | |
Completed |
NCT01279031 -
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
|
Phase 4 | |
Completed |
NCT01021761 -
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
|
Phase 4 | |
Completed |
NCT01001806 -
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
|
Phase 4 | |
Completed |
NCT01061463 -
Occupational Cataracts and Lens Opacities in Interventional Cardiology : the O'CLOC Study
|
N/A | |
Completed |
NCT00999492 -
Selection of Aspheric Diffractive Multifocal Intraocular Lens (IOLS) Based on Corneal Wavefront
|
Phase 4 | |
Completed |
NCT00542581 -
Acrysof Toric SN60T3corneal Astigmatism Between 0.75 and 1.00 D.
|
N/A | |
Completed |
NCT03708367 -
A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
|
N/A | |
Completed |
NCT05575063 -
Clinical Investigation of Healon EndoCoat Ophthalmic Viscosurgical Device (OVD)
|
N/A | |
Recruiting |
NCT05531292 -
PROOF-OF-CONCEPT STUDY FOR NEW INTRAOCULAR LENS, MODEL C0002
|
N/A | |
Completed |
NCT05058274 -
Clinical Results of a Monofocal Aspheric Bitoric Intraocular Lens With Plate Haptics in Hyperopic Eyes (HIPER-AT-TORBI)
|
||
Completed |
NCT05053399 -
Evaluation of the TECNIS Symfony® Toric Intraocular Lens
|
N/A | |
Recruiting |
NCT02639845 -
Eye Drop Application Monitor, Pilot Study
|
N/A | |
Completed |
NCT01684007 -
A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients
|
N/A | |
Completed |
NCT00827073 -
Comparison of Tetracaine 0.5% and Lidocaine 2% Jelly for Topical Phacoemulsification Cataract Surgery
|
N/A |